If you've spent any time reading about weight management in the last two years, you've almost certainly encountered the term GLP-1. These medications — originally developed for type 2 diabetes — have become the most significant development in obesity treatment in decades. But separating the science from the hype can feel overwhelming.
This guide is designed to give you a clear, unbiased foundation. No breathless promises, no scare tactics — just what the evidence says.
What Are GLP-1 Medications?
GLP-1 stands for glucagon-like peptide-1, a hormone your body naturally produces in the gut after eating. It plays a central role in blood sugar regulation and appetite signaling.
GLP-1 receptor agonists are synthetic versions of this hormone. They bind to the same receptors in your brain and gut, producing several effects:
- Reduced appetite — the "food noise" quieting effect patients frequently describe
- Slower gastric emptying — food stays in your stomach longer, increasing fullness
- Improved insulin sensitivity — better blood sugar control after meals
- Reduced glucagon secretion — less sugar released from the liver
The Major Players
The GLP-1 landscape has evolved rapidly. Here are the medications you'll encounter most often:
Semaglutide (Ozempic / Wegovy)
Manufactured by Novo Nordisk, semaglutide is the most widely recognized GLP-1 medication. Ozempic is FDA-approved for type 2 diabetes; Wegovy is approved specifically for chronic weight management. Same molecule, different dosing and indication.
Tirzepatide (Mounjaro / Zepbound)
Made by Eli Lilly, tirzepatide is a dual GIP/GLP-1 receptor agonist — meaning it activates two incretin pathways rather than one. Clinical trials have shown modestly superior weight loss compared to semaglutide, though head-to-head real-world data is still emerging.
Liraglutide (Saxenda)
An older daily-injection GLP-1 that preceded the weekly formulations. Still prescribed but largely supplanted by the newer options due to convenience and efficacy.
What to Realistically Expect
Clinical trial data shows average weight loss of:
- Semaglutide 2.4mg (Wegovy): ~15-17% of body weight over 68 weeks
- Tirzepatide 15mg (Zepbound): ~20-22% of body weight over 72 weeks
These are averages. Some patients see dramatically more; others, less. Response varies based on genetics, starting weight, diet, exercise habits, and dosage titration.
The most important thing to understand is that these medications are not a shortcut — they are a tool that makes sustainable lifestyle changes significantly more achievable.
Common Side Effects
The most frequently reported side effects are gastrointestinal:
- Nausea (especially during dose escalation)
- Constipation or diarrhea
- Reduced appetite (this is partly the mechanism of action)
- Fatigue during the first few weeks
Most patients report that GI side effects diminish significantly after 4-6 weeks at each dose level. Slow titration — gradually increasing the dose — is key to tolerability.
How to Get Started
There are two primary pathways to accessing GLP-1 medications:
- Your primary care physician or endocrinologist — traditional route, may require documented diet/exercise history
- Telehealth platforms — increasing number of online services offer consultations and prescriptions with home delivery
We review the major telehealth providers in our comparison table, evaluating pricing, medical oversight, and patient experience.
Compare providers
Ready to explore your options?
See our side-by-side comparison of the top GLP-1 telehealth providers — pricing, medications offered, and what real patients report.
View Provider ComparisonKey Questions to Ask Your Provider
Whether you're seeing your own doctor or consulting through a telehealth platform, ask these questions:
- Which GLP-1 medication do you recommend for my specific situation, and why?
- What's the titration schedule?
- How will we monitor for side effects and adjust?
- What lab work should I get before starting?
- What's the plan for maintaining results long-term?
The Bottom Line
GLP-1 medications represent a genuine paradigm shift in how we treat obesity — a condition that has historically been underserved by medicine. They are not magic, and they work best as part of a comprehensive approach that includes nutrition, movement, and behavioral changes. But for millions of people, they provide the metabolic support that makes those changes finally stick.